Introduction
CRO investors and analysts rely on a specific set of forward-looking metrics that are unique to the contract research model. Unlike pharmaceutical companies, where revenue visibility depends on patent expirations and pipeline success, CROs offer unusual revenue predictability through their contracted backlog. Understanding these metrics is essential for valuing CROs and for interpreting the quarterly earnings releases that move CRO stock prices.
Book-to-Bill Ratio: The Primary Forward Indicator
- Book-to-Bill Ratio
Net new business awards in a period divided by revenue recognized in the same period. A book-to-bill of 1.2x means the CRO booked $1.20 in new contracts for every $1.00 of revenue it recognized, implying its backlog is growing and future revenue will accelerate. The ratio is reported quarterly by all major public CROs and is the single most scrutinized metric on earnings calls.
The book-to-bill ratio tells you whether a CRO's business is expanding, stable, or contracting:
| Book-to-Bill | Signal | Market Reaction |
|---|---|---|
| Above 1.3x | Strong demand, potential acceleration | Positive, especially if sustained |
| 1.15-1.30x | Healthy growth, backlog building | Neutral to positive |
| 1.0-1.15x | Stable, modest backlog growth | Neutral |
| Below 1.0x | Backlog drawdown, future deceleration | Negative, potential selloff |
Several nuances matter when interpreting book-to-bill. First, the ratio is lumpy. Large pharma companies award multi-year contracts worth hundreds of millions of dollars, and the timing of a single mega-award can swing book-to-bill by 10-20 percentage points in a quarter. Analysts typically look at trailing twelve-month (LTM) book-to-bill to smooth this volatility. Second, cancellations reduce net new business. If a CRO books $2 billion in gross awards but has $300 million in cancellations, net new business is $1.7 billion. CROs that report gross versus net awards require careful adjustment.
Backlog: The Revenue Visibility Engine
Backlog represents the total remaining value of contracted work that has not yet been recognized as revenue. For large CROs, backlog typically represents 2-3 years of forward revenue, providing a level of visibility that is exceptional in healthcare and rare across any industry.
The key backlog metric is the conversion rate: the percentage of opening backlog that converts to revenue each quarter. Conversion rates typically run 8-12% per quarter, meaning roughly 35-45% of opening backlog converts to revenue within a year. This conversion rate is relatively stable over time, which is why backlog is such a reliable revenue predictor.
Burn Rate and Backlog Composition
Beyond the headline backlog number, the composition matters. A backlog heavily weighted toward early-stage study start-up work converts to revenue more slowly than one weighted toward active enrollment monitoring. Similarly, a backlog concentrated in a few large contracts carries more cancellation risk than one diversified across hundreds of engagements.
Management commentary on backlog composition is often more informative than the raw number. Key questions to ask: What percentage of backlog is from existing clients versus new relationships? What is the therapeutic area mix? What is the FSO versus FSP breakdown? How much is from biotech clients (higher cancellation risk if funding dries up) versus large pharma (lower cancellation risk but potentially slower growth)?
The next article maps the CRO competitive landscape, covering the Big Four CROs and the specialist players that compete on therapeutic depth rather than global scale.
Free Interview PDF Guide